CALGARY, AB, Aug. 30, 2023 /PRNewswire/ – Decibel Cannabis Company Inc. (the “Company” or “Decibel”) (TSXV: DB) (OTCQB: DBCCF), a market leader in premium cannabis and extract manufactured products, is pleased to announce that it has expanded its global footprint by entering into a supply agreement (the “Agreement”) to provide premium dried medical cannabis flower to 4C LABS, a healthcare, technology, and pharmaceutical company focused on virtual prescribing, pharmaceutical distribution and clinical development in cannabis based medicinal products for human health in the United Kingdom and Channel Islands (the “UK”).

Key Highlights

• Decibel to supply 4C LABS with Qwest branded, craft-quality Medical Cannabis for distribution to UK medical cannabis patients
• Decibel to grant strain exclusivity of rare and unique cultivars to be distributed by 4C LABS
• 3-year supply agreement
• Initial shipment expected before year end
• Minimum purchase commitments achieve exclusivity over certain genetics and QWEST brand in the UK

“We are excited to partner with 4C LABS, a leading organization in the growing medical cannabis industry in the UK, that echoes Decibel’s commitment to quality and patient care. Not only will this unlock a strong partnership and a new market for Decibel’s craft cannabis products, it also sets the stage for further growth into other European markets,” said Adam Coates, Chief Revenue Officer. “Decibel’s success with Qwest flower products in Canada and in Israel’s medical market reinforces the demand for premium cannabis products and the reputation we have built to service that demand.”

“4C LABS is building a patient focused best-in-class product line for the UK & Channel Islands, the Qwest craft flower line strengthens the top end of the 4C LABS product offerings. Decibel’s innovative craft quality Qwest flower products will fill an empty segment in the UK market and bring a world class BC Cannabis product to UK patients,” said Greg Dobbin, CEO 4C LABS. “Decibel’s success in Canada, the most competitive cannabis market in the world, is a product of hard work, innovation and attention to detail, qualities that will resonate with UK patients.”

About Decibel

Decibel is a consumer-focused cannabis company focused on delivering products that delight customers through a commitment to robust innovation and product quality. Leading brands General Admission, Qwest, and Vox are among its portfolio sold both across Canada and beginning to extend towards new countries to create a global footprint. Decibel operates a processing and manufacturing facility in Calgary, Alberta, and two cultivation facilities in Creston, British Columbia, and Battleford, Saskatchewan.

About 4C LABS

4C LABS is a patient focused healthcare, technology, and pharmaceutical company concentrating on virtual prescribing, pharmaceutical distribution and clinical development in cannabis based medicinal products (“CBMPs”) for human health. 4C LABS is committed to advancing scientific research, as well as enabling the regulation, distribution and prescribing of CBPMs in the UK and Channel Islands. Its work with leading scientists, specialist physicians, and pharmacists is underpinned with disruptive technologies that are driving an approach to treatment that prioritizes patients and evidence over stigma. 4C LABS works closely with Drug Science, the Cannabis Industry Council (CIC), The Medicines and Healthcare Products Regulatory Agency (MHRA) and the Care Quality Commission (CQC) to catalyze safe, regulated change in the medical landscape. 4C LABS is fully licensed in the UK with MS WDA, Schedule 1 Narcotics and Production licenses.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward Looking Information

This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking statements”) within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements.

In this news release, forward-looking statements relate to, among other things, the timing of the initial shipment; expectations with respect to the impact the Agreement will have on the Company’s business; expectations regarding international markets and the Company’s position therein; the Company’s ability to grow its brands into new and innovative territories as well as product formats, variations and other business plans and expectations.

Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: satisfaction of all international regulatory requirements, including applicable product testing; risks relating to delays; other regulatory changes and impacts; capital requirements; construction impacts; displacement requirements; global macro-economic events, conditions and factors; the ability to obtain and maintain licenses to retail cannabis products; review of the Company’s production facilities by Health Canada and maintenance of licenses (including any amendments thereto) from Health Canada in respect thereof; future legislative and regulatory developments involving cannabis, international export rules and regulations; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favourable terms; the labour market generally and the ability to access, hire and retain employees; general business, economic, competitive, political and social uncertainties; the satisfaction of conditions precedent under the Company’s credit facilities; and the delay or failure to receive board, regulatory or other approvals, including any approvals of the TSX Venture Exchange, as applicable.

There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on the forward-looking statements and information contained in this news release. Except as required by law, the Company assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.

These forward-looking statements are made as of the date of this press release and the Company disclaims any intent or obligation to update any forward-looking statements, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

SOURCE Decibel Cannabis Company Inc.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

Midwest Goods to promote Hempacco and Snoop Dogg’s partnership brand “Dogg lbs” nationwide

San Diego, California–(Newsfile Corp. – August 22, 2023) – Hempacco Co, Inc. (NASDAQ: HPCO) (“Hempacco”), a hemp smokables company Disrupting Tobacco’s nearly $1 Trillion industry with hemp cigarettes, smoking paper, and alternatives to nicotine tobacco, today announced it entered into a Distribution Agreement with Midwest Goods. Under the terms of the agreement, Midwest Goods will market and distribute Hempacco’s entire portfolio of hemp and CBD products, including Snoop Dogg’s Dogg lbs (pronounced “dog pounds”), The Real Stuff Hemp Smokables, Rick Ross’s Hemp Hop Smokables and Wraps, and Cheech & Chong Smokables and Wraps.

Hempacco recently launched Snoop Dogg’s “Dogg lbs” hemp-derived CBD and Delta-9 infused gummies at the Champs Show in Las Vegas, sharing a booth with Midwest Goods. The “Dogg lbs” Delta-9 Gummy brand comes in two presentations: a 5-pack and a 20-pack pouch, and three different flavors: grape, blue raspberry, and cherry lemon.

“We are excited to be a part of the launch of Snoop’s new brand, Dogg lbs,” said Midwest Goods. “Our strategic partnership with Hempacco will help spread the ‘Dogg lbs’ brand across the US.”

HPCO Midwest Goods Collaboration

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/8020/177993_hpco_midwest_goods_collaboration.jpg

“This new partnership not only strengthens our presence nationwide but also reinforces our commitment to building the brand,” said Sandro Piancone, CEO of Hempacco. “By working closely with Midwest Goods, we aim to foster long-lasting relationships with retailers while delivering exceptional customer service and product availability.”

The signing of this new distributor signifies a significant step forward for Hempacco’s expansion plans. The Company looks forward to building strong partnerships as they continue revolutionizing the hemp industry through innovation, sustainability, and unwavering commitment to customer satisfaction.

About Hempacco
Hempacco Co., Inc.’s goal is Disrupting Tobacco’s nearly $1 trillion industry with herb and hemp-based alternatives to nicotine cigarettes by manufacturing and marketing herb, spice, and cannabinoid smokables and rolling paper. Hempacco owns The Real Stuff functional hemp cigarette and rolling paper brand.

Hempacco’s operating segments include:

1. Manufacturing of smokables, hemp rolling paper, and cannabinoid sticks
2. Smokable technology development
3. The Real Stuff brand of functional smokables and rolling paper
4. Cheech and Chong Hemp Cigarettes and Hemp Hop Smokables with Rick Ross
5. Snoop Dogg Joint Venture of Hemp-Derived Products

Learn more at www.hempacco.com.

Order products at www.realstuffsmokables.com.

About Midwest Goods

Midwest Distribution is a Wholesale B2B distributor of vape electronic cigarette supplies and smoke shop, headshop & dispensary supplies in the United States. To learn more, visit www.midwestgoods.com.

For investor inquiries, please contact:

Sandro Piancone, CEO
Investor Relations: ir@hempaccoinc.com
619-779-0715

Safe Harbor Statement

This press release contains forward-looking statements. In addition, from time to time, we or our representatives may make forward-looking statements orally or in writing. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance, including: our financial performance and projections; our growth in revenue and earnings; and our business prospects and opportunities. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as “may,” “should,” “expects,” “anticipates,” “contemplates,” “estimates,” “believes,” “plans,” “projected,” “predicts,” “potential,” or “hopes” or the negative of these or similar terms. In evaluating these forward-looking statements, you should consider various factors, including: (i) potential failure to meet projected development and related targets; (ii) changes in applicable laws or regulations that may impact our products and business; (iii) the effect of the COVID-19 pandemic on the Company and its current or intended markets; and (iv) other risks and uncertainties described herein, as well as those risks and uncertainties discussed from time to time in other reports and other public filings with the Securities and Exchange Commission (the “S.E.C.”) by the Company. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking events discussed in this press release and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties, and assumptions about us. We are not obligated to publicly update or revise any forward-looking statement, whether as a result of uncertainties and assumptions, the forward-looking events discussed in this press release and other statements made from time to time by us or our representatives might not occur.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

TORONTO, Aug. 22, 2023 /CNW/ – Humble & Fume Inc. (CSE: HMBL) (OTCQX: HUMBF) (“Humble” or the “Company”), a leading North American distributor of cannabis and cannabis accessories, today bolstered its expansion plans as it announced an additional $4 million USD investment by Green Acre Capital Distribution Corp. (“Green Acre”) into HC Solutions Holdings Inc. (“HCI”), a joint venture company established by Humble and Green Acre.  The focus of this venture continues to be the strategic distribution of cannabis products across the United States, with a primary focus on California.

Green Acre has financed its investment through an option agreement with Johnson Brothers, a leading wine, spirits, and beer distributor in the United States. Further information on the JV, Green Acre and Johnson Brothers is set out in the company’s Nov. 15, 2021, and April 25, 2022, press releases.  This innovative financing approach aligns with Humble’s ethos of seeking strategic partnerships that leverage industry expertise and resources to fuel expansion.

Green Acre and Johnson’s commitment, in the form of this substantial financial infusion, underscores their steadfast support for Humble’s growth trajectory within the cannabis distribution landscape. This augmented partnership capitalizes on the synergies between the parties, amplifying their combined influence in the rapidly evolving cannabis market.

“Securing this additional $4 million USD investment represents another significant step forward in our strategic plan for growth and market presence,” commented Jakob Ripshtein, CEO of Humble. “We are proud to deepen our relationship with our partners and appreciate their unwavering confidence in our ability to drive forward within the competitive landscape of cannabis distribution.”

By leveraging the financial backing and strategic acumen of its partners, Humble is poised to seize new opportunities, broaden its product offerings, and enhance its operational capabilities. The investment increases Green Acre’s ownership stake in HCI from 50.2% to 75%, while Humble retains the remaining 25%.

Green Acre has also granted to Humble an option for a period of six months to acquire 50% of the common shares of HCI acquired by Green Acre pursuant to the subscription described above for an aggregate purchase price of $2 million USD.

For more information about the joint venture, Green Acre Capital, and Johnson Brothers, please refer to the Company’s previous press releases dated November 15, 2021, April 25, 2022, and September 13, 2022.

About Humble & Fume Inc.

Humble & Fume Inc. (CSE: HMBL; OTCQX: HUMBF) is a premier distributor of cannabis products and accessories across North America. With a commitment to excellence, innovation, and market leadership, Humble & Fume is dedicated to shaping the future of cannabis distribution and enhancing consumer experiences.

Forward-Looking Information and Statements

This news release contains “forward-looking information” within the meaning of applicable securities laws relating to, the Company’s assessment of the cannabis market in the United States generally and specifically, the state of California, and the expected results for brand partners of the Company. Any such forward-looking statements may be identified by words such as “expects”, “anticipates”, “intends”, “contemplates”, “believes”, “projects”, “plans” and similar expressions. Readers are cautioned not to place undue reliance on forward-looking statements. Statements about, among other things, the potential for Johnson Brothers, through Green Acre, to increase its ownership percentage in the joint venture, the potential impact on brands that engage Humble for their distribution and/or sales agency and the future of the cannabis industry in California and across the United States, including the anticipated ongoing consumer demand, are all forward-looking information. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance, or achievements to be materially different from those implied by such statements. Although such statements are based on management’s reasonable assumptions, there can be no assurance that such forward-looking statements will occur as described herein. The Company assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances or actual results unless required by applicable law. Readers are encouraged to refer to the Company’s disclosure available on its SEDAR profile (at www.sedar.com) for information as to the risks and other factors which may effect the Company’s business objectives and strategic plans.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

Second Leading Consumer Hemp/Cannabis Brand Adopts 22nd Century’s Turn-Key Contract Development and Manufacturing Plus Distribution (CDMO+D) Solution

Previously Announced Cookies Agreement Now Targeting More Than 200 Wholesale Distributors

Combined Cumulative Value of New License and Distribution Agreements Executed to Date Expected to Exceed $140 Million Over Contract Terms

BUFFALO, N.Y., May 02, 2023 (GLOBE NEWSWIRE) — 22nd Century Group, Inc. (Nasdaq: XXII), a leading biotechnology company dedicated to improving health with reduced nicotine tobacco, hemp/cannabis and hops advanced plant technologies, today announced its second exclusive license, manufacturing and distribution agreement (the “Agreement”) in the hemp/cannabis industry, signed with Old Pal, LLC, a widely recognized consumer hemp/cannabis company started in California and now operating in eight states.

“Old Pal is the second leading consumer hemp/cannabis brand to adopt 22nd Century’s innovative strategic license, manufacturing and distribution agreement. This model enables brands to focus on product development, customer engagement and marketing while we provide expansive access to mass market channels urgently seeking new, high-margin, high-velocity products to meet growing consumer demand,” said James A. Mish, Chief Executive Officer of 22nd Century.

Initially launched in California in 2018, Old Pal quickly gained recognition for its nostalgic branding. Today, the brand has expanded its reach and struck a chord with millions of daily consumers by paying homage to a simpler era, where hemp/cannabis was uncomplicated, neighbors knew each other by name, and the sense of community was significant. In addition, Old Pal’s continuously growing line of apparel, accessories, and home goods has firmly established it as a prominent cultural figure in the world of cannabis.

The exclusive license with 22nd Century covers Old Pal branded non-Delta-9 THC, hemp derived cannabinoid consumer products and accessories. Similar to 22nd Century’s first single-source integrated production, sales and distribution agreement in hemp/cannabis, signed with Cookies, the Old Pal agreement will leverage 22nd Century’s industry leading formulation, ingredient and manufacturing infrastructure plus the Company’s turn-key sales and distribution platform for alternative consumer products in a complete go-to-market solution.

Combined, the Company estimates that its agreements with Cookies and Old Pal represent more than $140 million in revenue opportunity with very attractive margins over the terms of the contracts. 22nd Century is now advancing its initial mass market retail efforts for these products across the United States, leveraging a network of more than 200 wholesale distributors. The Company continues to pursue additional exclusive license opportunities with industry brands interested in its innovative integrated solution.

About 22nd Century Group, Inc.
22nd Century Group, Inc. (Nasdaq: XXII) is a leading biotechnology company focused on utilizing advanced alkaloid plant technologies to improve health and wellness through tobacco harm reduction, reduced nicotine tobacco, hemp/cannabis and hops. With dozens of patents allowing it to control nicotine biosynthesis in the tobacco plant, the Company has developed proprietary reduced nicotine content (RNC) tobacco plants and cigarettes, which have become the cornerstone of the FDA’s Comprehensive Plan to address the widespread death and disease caused by smoking. The Company received the first and only FDA Modified Risk Tobacco Product (MRTP) authorization of a combustible cigarette in December 2021. In tobacco, hemp/cannabis and hop plants, 22nd Century uses modern plant breeding technologies, including genetic engineering, gene-editing, and molecular breeding to deliver solutions for the life science and consumer products industries by creating new, proprietary plants with optimized alkaloid and flavonoid profiles as well as improved yields and valuable agronomic traits.

Learn more at xxiicentury.com, on Twitter, on LinkedIn, and on YouTube.

Learn more about VLN® at tryvln.com.

Cautionary Note Regarding Forward-Looking Statements

Except for historical information, all of the statements, expectations, and assumptions contained in this press release are forward-looking statements. Forward-looking statements typically contain terms such as “anticipate,” “believe,” “consider,” “continue,” “could,” “estimate,” “expect,” “explore,” “foresee,” “goal,” “guidance,” “intend,” “likely,” “may,” “plan,” “potential,” “predict,” “preliminary,” “probable,” “project,” “promising,” “seek,” “should,” “will,” “would,” and similar expressions. Actual results might differ materially from those explicit or implicit in forward-looking statements. Important factors that could cause actual results to differ materially are set forth in “Risk Factors” in the Company’s Annual Report on Form 10-K filed on March 9, 2023. All information provided in this release is as of the date hereof, and the Company assumes no obligation to and does not intend to update these forward-looking statements, except as required by law.

Investor Relations & Media Contact
Matt Kreps
22nd Century Group, Inc.
Investor Relations
mkreps@xxiicentury.com
214-597-8200

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

LOS ANGELES (PRWEB) JANUARY 30, 2023

WEEDAR, a unique loyalty and distribution ecosystem that combines engaging AR-powered shopping experiences and gamified loyalty programs for cannabis brands, today announced that it has raised $1.5 million in a Seed Round of funding led by an anonymous private investor. The investment brings the company’s total fundraising to date to $2.3 million. The raised funds will be used to expand and improve the existing feature set, and scale marketing as the company continues building its industry-first platform that’s already helping cannabis brands fuel sales and strengthen customer retention.

Consumers using WEEDAR can shop their favorite brands in 3D augmented reality, as opposed to generic product catalogs, get access to exclusive, beautifully packaged product drops created in collaboration with trendy artists, and receive NFTs for their purchases. Customers can then trade or resell the NFTs, making WEEDAR the first and only platform where consumers can actually make money buying weed. Customers can also engage in gamified in-app experiences and collect points for each win. These points are stored in a virtual Stash Box, and can be exchanged for discounts and merch, such as exclusive customized bongs or grinders.

Brands can market their products through the WEEDAR platform and create customizable loyalty programs for their consumers, generating more sales, driving customer loyalty and boosting retention rates. Brands can also opt for a white-label solution, which includes a fully customized app with branded AR-powered experiences and tailor-made loyalty schemes. Additionally, brands get access to advanced sales analytics that provide insight into consumption patterns across regions, which enables improved product distribution, sales and localized offerings.

“Cannabis is the United States’ fastest-growing market. VCs are pouring in cash and consumers are happily hopping on board. However, the marketing aspect seems to be stuck in the ‘90s. Most cannabis brands are clinging on to the old-school points program, which is outdated, boring and ties clients to one point of sale. With WEEDAR they can access limited edition products with unique packaging online, check out the item and its contents in AR, collect points, and redeem discounts and goodies. Our ultimate goal is to integrate these features with all points of sales — online and offline — to create a unified loyalty platform, enabling consumers to get the most out of shopping with their favorite brands anywhere and any time,” said Jonathan Bohun, founder and CEO of WEEDAR.

Currently operating in California, WEEDAR has teamed up with 12 delivery hubs serving a population of 2 million with over 700 items, which are visualized in the Californian cannabis market’s biggest library of 3D models. The company plans to expand to Washington, New York, Florida and Michigan in 2023. WEEDAR has shown consistent and sustainable month-over-month growth of 30% and has already signed with the biggest names on the market, including The Cure Company and Kushstock Festival, with more partners signing up.

ABOUT WEEDAR
Founded in 2021, WEEDAR is a revolutionary loyalty and distribution platform offering engaging AR-powered distribution and gamified loyalty programs for cannabis brands. Currently operating in California, the solution helps cannabis brands boost sales, drive customer retention and loyalty through immersive and engaging customizable shopping experiences. WEEDAR’s unique combination of features is used by leaders in the cannabis market, including The Cure Company, to fuel their marketing and sales operations.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

DENVER, CO / ACCESSWIRE / November 22, 2022 / Leafbuyer Technologies, Inc. (OTCQB:LBUY) (“Leafbuyer” or “the Company”) a leading cannabis technology and marketing platform, announced today the company had closed three large multi-state operators (MSOs) with a contract total of over $450,000 in annual revenue.

Leafbuyer continues to grow at nearly twice the industry rate. Mark Breen, Chief Operating Officer of Leafbuyer, stated, “This is a testament to the hard work our team has spent in building segmentation, which allows our customers to send targeted campaigns, offer deeper integrations, as well as deploying IOS and Google Play Store Applications.” Breen added, “We are seeing more and more larger MSO’s turn to Leafbuyer Technologies for custom solutions and true partnerships where we can continue to build out custom requests.” Leafbuyer will report current quarter results in early February.

About Leafbuyer Technologies, Inc.

Leafbuyer Technologies is one of the most comprehensive marketing technology providers in the cannabis industry. Hundreds of cannabis businesses use the Leafbuyer texting and loyalty platform and the Custom App solution to engage with current and potential customers. Leafbuyer.com is a robust online resource for cannabis consumers, and the company’s partnerships with other websites have created a national network of cannabis deals and information that reaches millions of consumers every month.

Learn more at www.tech.leafbuyer.com

Contact:

Leafbuyer Technologies, Inc.
Vida Almich 720.427.3927
[email protected]

Cautionary Statement Regarding Forward-Looking Information Safe Harbor Statement

This press release may contain forward-looking statements which are based on current expectations, forecasts, and assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially from those anticipated or expected, including statements related to the amount and timing of expected revenues and any payment of dividends on our common and preferred stock, statements related to our financial performance, expected income, distributions, and future growth for upcoming quarterly and annual periods. These risks and uncertainties are further defined in filings and reports by the Company with the U.S. Securities and Exchange Commission (SEC). Actual results and the timing of certain events could differ materially from those projected in the forward-looking statements due to several factors detailed from time to time in our filings with the Securities and Exchange Commission. Reference is hereby made to cautionary statements set forth in the Company’s most recent SEC filings.

SOURCE: Leafbuyer Technologies, Inc.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

New distribution facility supports rapidly growing demand for hemp/cannabis products

BUFFALO, N.Y., Nov. 16, 2022 (GLOBE NEWSWIRE) — GVB Biopharma, a 22nd Century Group company (Nasdaq: XXII), today announced that it has opened a new, strategically-located distribution facility in the Netherlands to support its growing business in Europe, the Middle East, and Africa (EMEA). The new distribution facility will increase existing and new customer access to GVB’s quality hemp/cannabis products, speed up transaction flow, and optimize cross border tax and customs treatment.

Recent increases in GVB’s U.S. manufacturing capacity are complementary to the advent of the Company’s Netherlands distribution facility. Additional capacity is in part earmarked to satisfy increasing demand in European markets where margins are higher than in the U.S.

“We are excited to expand our business operations in Europe, allowing our customers and partners to access quality products in a more efficient manner,” said James A. Mish, chief executive officer of 22nd Century Group. “With our new Netherlands distribution facility, we can now deliver product to our partners in half the time and better serve our growing customer base with quality distillate and isolates. In Europe, the hemp/cannabis industry is expanding rapidly and is expected to reach €3.2 billion by 2025. Our new facility will allow us to capture more of that market share, scale our operations, and expand our customer base in this region.”

About GVB Biopharma
GVB Biopharma, a 22nd Century company, is a global-scale specialty ingredient supplier and contract development & manufacturing organization (CDMO) with manufacturing locations in Nevada and Oregon. GVB is the largest merchant provider of cannabinoid extracts and isolates in North America with a focus on cannabidiol (CBD) and cannabigerol (CBG) extracted and refined at an industrial scale into distillates and isolates. GVB Biopharma’s facilities are NSF International audited and are cGMP Registered for dietary supplements manufacturing. GVB is widely regarded as a best-in-class operator with a leading position in the hemp-derived active ingredients market, with around 15% market share and growing. GVB is also a white-label contract manufacturer of tinctures, gel capsules, gummies, mints, tablets, topical, and vape offerings.

About 22nd Century Group, Inc.
22nd Century Group, Inc. (Nasdaq: XXII) is a leading agricultural biotechnology company focused on tobacco harm reduction, reduced nicotine tobacco and improving health and wellness through plant science. With dozens of patents allowing it to control nicotine biosynthesis in the tobacco plant, the Company has developed proprietary reduced nicotine content (RNC) tobacco plants and cigarettes, which have become the cornerstone of the FDA’s Comprehensive Plan to address the widespread death and disease caused by smoking. The Company received the first and only FDA MRTP authorization of a combustible cigarette in December 2021. In tobacco, hemp/cannabis, and hop plants, 22nd Century uses modern plant breeding technologies, including genetic engineering, gene-editing, and molecular breeding to deliver solutions for the life science and consumer products industries by creating new, proprietary plants with optimized alkaloid and flavonoid profiles as well as improved yields and valuable agronomic traits.

Learn more at xxiicentury.com, on Twitter, on LinkedIn, and on YouTube.

Learn more about VLN^® at tryvln.com.

Cautionary Note Regarding Forward-Looking Statements
Except for historical information, all of the statements, expectations, and assumptions contained in this press release are forward-looking statements. Forward-looking statements typically contain terms such as “anticipate,” “believe,” “consider,” “continue,” “could,” “estimate,” “expect,” “explore,” “foresee,” “goal,” “guidance,” “intend,” “likely,” “may,” “plan,” “potential,” “predict,” “preliminary,” “probable,” “project,” “promising,” “seek,” “should,” “will,” “would,” and similar expressions. Actual results might differ materially from those explicit or implicit in forward-looking statements. Important factors that could cause actual results to differ materially are set forth in “Risk Factors” in the Company’s Annual Report on Form 10-K filed on March 1, 2022, and in the Company’s Quarterly Report filed on August 9, 2022. All information provided in this release is as of the date hereof, and the Company assumes no obligation to and does not intend to update these forward-looking statements, except as required by law.

GVB Biopharma U.K. & Europe Contact
Karl Muldowney
Commercial Director, GVB U.K. & Europe
[email protected]

Investor Relations & Media Contact
Mei Kuo
22nd Century Group, Inc.
Director, Communications & Investor Relations
[email protected]

Darrow Associates Investor Relations
Matt Kreps
[email protected]

Source: 22nd Century Group, Inc

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

LAS VEGAS, NV (October 24, 2022) GPO Plus, Inc. (OTCQB: GPOX), a publicly traded company of diversified Group Purchasing Organizations (GPOs) uses the power of Group Purchasing to save businesses money, announced Chris Harter has been appointed to the Board of Directors.

Chris Harter has enjoyed a distinguished career focusing on real estate private equity, finance and emerging industries including the hemp and cannabis sectors. While Chris as a young man is just getting started, his efforts lead the growth of a single family home investment portfolio from $1 Million to $70 Million in a 6 year span.

Chris began his career by forming his own executive search firm, Career Estimate. Within 18 months, Career Estimate was acquired by industry leader Arkadis Inc. and Chris began investing in startups including his own chain of CBD Stores, a golf course, and early stage crypto ventures.

Chris brings a wealth of 20+ year relationships to GPOX in retail as well as in raw materials, and external sales operations with Independent Sales Organizations (ISO) commonly referred to in the industry as “jobbers” nationwide.

“I’m very excited to join GPOX as a board member where I can add value to the strategic planning and execution of the vision created by Brett (Pojunis) and his team,” said Chris Harter. Harter continued “I’m thrilled to continue to foster growth and make connections in an industry where I have devoted much of my life’s work. I look forward to building new relationships and leveraging those I have built to achieve new levels of success.”

GPOX Chairman and CEO Brett H. Pojunis, said, “Chris is an ideal board member and resource to help GPOX scale and further its mission.” Pojunis stated, Chris has invaluable experience and his connections are second to none.”

About DISTRO+

We help retailers save money + simplify purchasing!

DISTRO+ is a Group Purchasing Organization (GPO) + distributor of premium products for the emerging specialty retailer sector and wholesalers. Through the power of Group Purchasing, DISTRO+ offers its network of customers (we call them “Members”) competitive pricing with low MOQs that realize similar discounts as major retailers with large buying power. Visit DISTRO.Plus for more information.

About GPOPlus+ (GPOX)

Headquartered in Las Vegas, Nevada, GPOPlus+ (OTCQB: GPOX) is a publicly traded company of diversified industry-specific Group Purchasing Organizations (GPOs). Our Purpose is to create efficient GPOs and our Mission is to create value for our GPO Members, partners, and suppliers while creating long term shareholder value.

Our Mantra:
We Aggregate, Negotiate + Share!

• Aggregate – We aggregate the purchasing power of our Members.
• Negotiate – We leverage buying power to negotiate
• Share – We share the discounts with our Members and save them money.

For more information please visit www.GPOPlus.com. To activate your free GPOX Investor Account at www.GPOPlus.com/ir.

Information about Forward-Looking Statements

This press release contains “forward-looking statements” that include statements regarding expected financial performance and growth information relating to future events. Forward-looking statements include statements with respect to beliefs, plans, objectives, goals, expectations, anticipations, assumptions, estimates, intentions, and future performance, and involve known and unknown risks, uncertainties and other factors, which may be beyond the control of the Company and its officers and managers, and which may cause actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Forward-looking statements should not be read as a guarantee of future performance or results and will not necessarily be accurate indications of the times at, or by which, that performance or those results will be achieved. Forward-looking statements are based on information available at the time they are made and/or management’s good faith belief as of that time with respect to future events and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in, or suggested by, the forward-looking statements. Important factors that could cause these differences include, but are not limited to; inability to gain or maintain licenses, reliance on unaudited statements, the Company’s need for additional funding, governmental regulation of the cannabis industry, the impact of competitive products and pricing, the demand for the Company’s products, and other risks that are detailed from time-to-time in the Company’s filings with the United States Securities and Exchange Commission.  All statements other than statements of historical fact are statements that could be forward-looking statements. You can typically identify these forward-looking statements through use of words such as “may,” “will,” “can” “anticipate,” “assume,” “should,” “indicate,” “would,” “believe,” “contemplate,” “expect,” “seek,” “estimate,” “continue,” “plan,” “point to,” “project,” “predict,” “could,” “intend,” “target,” “potential,” and other similar words and expressions of the future. The Company expresses its expectations, beliefs and projections in good faith and believes that its expectations reflected in these forward-looking statements are based on reasonable assumptions. However, there is no assurance that these expectations, beliefs and projections will prove to have been correct. Such statements reflect the current views of the Company with respect to its operations and future events, and are subject to certain risks, uncertainties and assumptions relating to its proposed operations, including the risk factors set forth herein. Should one or more of these risks or uncertainties materialize or should the underlying assumptions prove incorrect, the Company’s actual results may vary significantly from those intended, anticipated, believed, estimated, expected or planned. In light of these risks, uncertainties and assumptions, any favorable forward-looking events discussed herein might not be realized and occur. The Company has no obligation to update or revise its forward-looking statements, whether as a result of new information, future events or otherwise. For a more detailed description of the risk factors and uncertainties affecting GPO Plus, Inc. GPOX, please refer to the Company’s recent Securities and Exchange Commission filings, which are available at www.sec.gov. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

Shareholder Success Team + Investor Relation Contacts:

Brett H. Pojunis, CEO
Email: [email protected]
Shareholder’s Line: 855.935.GPOX (4769)

Click here to view the full release on Globe Newswire: https://www.globenewswire.com/news-release/2022/10/24/2540214/0/en/GPOPlus-Appoints-Chris-Harter-as-a-Member-of-the-Board-of-Directors.html

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

• Partnership Expands the Availability of VLN^® Reduced Nicotine Content Cigarettes to Specialty Point of Sale Retail Sites across Colorado

BUFFALO, N.Y., Oct. 03, 2022 (GLOBE NEWSWIRE) — 22nd Century Group, Inc. (Nasdaq: XXII), a leading agricultural biotechnology company dedicated to improving health with reduced nicotine tobacco, hemp/cannabis, and hops advanced plant technologies, today announced that the Company has added Creager Mercantile as a distribution partner to expand availability and support for its VLN^® reduced nicotine content cigarette products in the state of Colorado.

Operating since 1958, Creager is a well-known wholesale supplier for a wide array of cigarette retailers including hospital gift shops, gas stations, and tobacco shops across the state. The company supports more than 1,000 stores across numerous specialty and retail store brands. Combined with 22nd Century’s previously announced partnership with Eagle Rock Distributing Company, the Company now has access to thousands of potential retail sites across the state that could be serviced by its VLN^® distribution partners.

22nd Century Group’s proprietary VLN^® cigarettes smoke, smell, and taste like a cigarette but contain approximately 95% less nicotine than conventional cigarettes, a level shown to be non-addictive. As noted on the packaging, VLN^® is the only cigarette in the world purposefully designed to “Help You Smoke Less.”

“We are excited to work with 22nd Century Group to make VLN^® available to adult smokers in Colorado who are looking for a new way to cut their ties to nicotine,” said Chip Creager, President of Creager Mercantile. “Creager supports a diverse array of specialty stores, often advising retailers on the best new products to add to their shelves. We believe that VLN^®’s uniqueness as the first and only cigarette designed specifically to help smokers smoke less makes it an important and attractive product for adult smokers, and we will be actively working with our retail partners to launch VLN^® to their stores in the coming months.”

“Creager opens up an entire additional channel of specialty retail and tobacco suppliers across the state of Colorado, and its direct role in product recommendations and store support make it an ideal partner for 22nd Century’s VLN^® rollout,” said John J. Miller, president of 22nd Century’s Tobacco Business. “We look forward to working directly with Creager to place VLN^® on as many shelves as possible, making our important new product broadly available in as many locations as possible where traditional combustible cigarettes are sold.”

More information about Creager can be found online at https://creagermerc.com/.

22nd Century Group’s decision to launch in Colorado follows the exceptional pilot results in Chicago and the Company’s plans to have distribution and retail partnerships in place to support the expanding availability of VLN^® to adult smokers across the country. The Chicago pilot demonstrated that in-store outreach was highly effective, and once adult smokers had tried VLN^®, the vast majority were quick to recommend VLN^® to other adult smokers. Specialty distribution such as Creager, which supports additional functions such as merchandising and product advice, expands the awareness of VLN^®’s highly differentiated value proposition in key retail channels.

About 22nd Century Group, Inc.
22nd Century Group, Inc. (Nasdaq: XXII) is a leading agricultural biotechnology company focused on tobacco harm reduction, reduced nicotine tobacco and improving health and wellness through plant science. With dozens of patents allowing it to control nicotine biosynthesis in the tobacco plant, the Company has developed proprietary reduced nicotine content (RNC) tobacco plants and cigarettes, which have become the cornerstone of the FDA’s Comprehensive Plan to address the widespread death and disease caused by smoking. The Company received the first and only FDA MRTP authorization of a combustible cigarette in December 2021. In tobacco, hemp/cannabis, and hop plants, 22nd Century uses modern plant breeding technologies, including genetic engineering, gene-editing, and molecular breeding to deliver solutions for the life science and consumer products industries by creating new, proprietary plants with optimized alkaloid and flavonoid profiles as well as improved yields and valuable agronomic traits.

Learn more at xxiicentury.com, on Twitter, on LinkedIn, and on YouTube.

Learn more about VLN^® at tryvln.com.

Cautionary Note Regarding Forward-Looking Statements
Except for historical information, all of the statements, expectations, and assumptions contained in this press release are forward-looking statements. Forward-looking statements typically contain terms such as “anticipate,” “believe,” “consider,” “continue,” “could,” “estimate,” “expect,” “explore,” “foresee,” “goal,” “guidance,” “intend,” “likely,” “may,” “plan,” “potential,” “predict,” “preliminary,” “probable,” “project,” “promising,” “seek,” “should,” “will,” “would,” and similar expressions. Actual results might differ materially from those explicit or implicit in forward-looking statements. Important factors that could cause actual results to differ materially are set forth in “Risk Factors” in the Company’s Annual Report on Form 10-K filed on March 1, 2022, and in the Company’s Quarterly Report filed on August 9, 2022. All information provided in this release is as of the date hereof, and the Company assumes no obligation to and does not intend to update these forward-looking statements, except as required by law.

Investor Relations & Media Contact
Mei Kuo
22nd Century Group, Inc.
Director, Communications & Investor Relations
[email protected]

Darrow Associates Investor Relations
Matt Kreps
T: 214-597-8200
[email protected]

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

SCOTTSDALE, AZ / ACCESSWIRE / August 18, 2022 / Today CBD Life Sciences (OTC PINK:CBDL) through its wholly owned subsidiary, LBC Bioscience Inc. announces today that the company is taking an innovative approach by introducing a product that is infused with both Delta-8 & Delta-9.

LBC Bioscience Inc. is yet again dominating the competition by creating new products along with continuous experimenting, and this product is a huge step forward for overall growth of the company! The delicious Green Apple flavored product the company is introducing are Infused Gummies with 15MG of Delta-8 & 10MG of Delta-9 per gummy and will come in a 15-Count Jar. This specific product is ideal for easing the mind while having staying focused all at the same time! All products are carefully blended to ensure consistency along with Third Party Lab Testing for verification. This product will be available in store as of today with the LBC website to follow within the next couple of days.

President & CEO Lisa Nelson states, “We have been working diligently to experiment and create a new product to deliver to our consumers & beloved shareholders and we will continue to keep the public updated moving forward!”

The number of benefits CBD has is tremendous! These benefits may help with behavioral/neurological complications such as ADD/ADHD, anxiety, autism, bipolar, OCD, PTSD, epilepsy, Parkinson’s, osteoporosis, and ALS. CBD may also benefit pain management that can stem from headaches/migraines, arthritis, cramps, spinal injuries, and fibromyalgia. CBD has been found to also have gastrointestinal benefits with gastro-disorders and complications such as anorexia, cachexia, Crohn’s, diabetes, and nausea. Physical complications/disorders such as muscular dystrophy and even immune system-based deficiencies and other complications such as cancer and hypertension, even our bodies way and ability to maintain homeostasis have all been said to benefit from CBD.

LBC BIOSCIENCE INC. ONLINE STORE

LBC BIOSCIENCE’S Online Emporium

LBC Bioscience Inc. is well stocked already as it is with some very high-quality CBD offerings – all at very reasonable prices. Check out LBC Bioscience Inc’s newest product offerings including its: 100MG CBD Bath Bombs in a variety of scents, Delta 8 Gummies, 1500 MG Premium Berry Drops, and a variety of all-new Skincare products. Or shop our top selling products (based on order frequency) which include our CBD Pain Cream, CBD Oils and CBD Pet Treats.

Become a Distributor

• Large Selection of Products (over 50 items and growing)
• 100% USA Made Products “organic & kosher.”
• All Products are THC-FREE (they contain 0.00% THC)
• Weekly Deals (new deals every week)

LBC Bioscience Inc. accepts: Visa, MasterCard, American Express, Discover etc.

Shareholders and interest holders may also stay current with LBC Bioscience Inc Updates:

LBC Bioscience Inc’s Main Website at www.lbcbioscienceinc.com
Twitter: https://www.twitter.com/lbcbioscience
Facebook: https://www.facebook.com/lbcbioscience
Instagram: https://www.instagram.com/lbcbioscience

About LBC Bioscience Inc.
LBC Bioscience Inc. is a wholly owned subsidiary of CBD Life Sciences Inc. LBC has developed and is retailing/wholesale a full line of cannabidiol based organic products including CBD Drops, Gumballs, Honey Sticks, Pain Relief Creams, Anxiety & Sleep Supplements, Edibles, Coffee, Skincare Line, Pet Line, Tablets and more. LBC’s products can be viewed and purchased on the Company’s website at www.lbcbioscienceinc.com.

Ten Associates LLC
Contact: Thomas E. Nelson
Telephone: (480) 326-8577
Email: [email protected]
Website: www.tenassociatesllc.com

Forward-Looking Statements

Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements. Actual results may differ materially from those described in forward-looking statements and are subject to risks and uncertainties. See CBD Life Sciences, Inc’s, Inc.’s filings with OTC Markets, which may identify specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements.

Safe Harbor Statement

This release includes forward-looking statements, which are based on certain assumptions and reflects management’s current expectations. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Some of these factors include: general global economic conditions; general industry and market conditions, sector changes and growth rates; uncertainty as to whether our strategies and business plans will yield the expected benefits; increasing competition; availability and cost of capital; the ability to identify and develop and achieve commercial success; the level of expenditures necessary to maintain and improve the quality of services; changes in the economy; changes in laws and regulations, including codes and standards, intellectual property rights, and tax matters; or other matters not anticipated; our ability to secure and maintain strategic relationships and distribution agreements. The Company disclaims any intention or obligation to update or revise any forward-looking ability to secure and maintain strategic relationships and distribution agreements. The Company disclaims any intention or obligation to update or revise any forward-looking

SOURCE: CBD Life Sciences Inc.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.